- Home
- RCON vs TCRX Comparison
RCON vs TCRX Comparison
Compare RCON & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCON
- TCRX
- Stock Information
- Founded
- RCON 2007
- TCRX 2018
- Country
- RCON China
- TCRX United States
- Employees
- RCON N/A
- TCRX N/A
- Industry
- RCON Oilfield Services/Equipment
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RCON Energy
- TCRX Health Care
- Exchange
- RCON Nasdaq
- TCRX Nasdaq
- Market Cap
- RCON 86.1M
- TCRX 91.7M
- IPO Year
- RCON 2009
- TCRX 2021
- Fundamental
- Price
- RCON $2.24
- TCRX $1.81
- Analyst Decision
- RCON
- TCRX Strong Buy
- Analyst Count
- RCON 0
- TCRX 5
- Target Price
- RCON N/A
- TCRX $9.40
- AVG Volume (30 Days)
- RCON 176.0K
- TCRX 221.8K
- Earning Date
- RCON 09-26-2025
- TCRX 08-12-2025
- Dividend Yield
- RCON N/A
- TCRX N/A
- EPS Growth
- RCON N/A
- TCRX N/A
- EPS
- RCON N/A
- TCRX N/A
- Revenue
- RCON $8,996,572.00
- TCRX $6,961,000.00
- Revenue This Year
- RCON N/A
- TCRX $255.18
- Revenue Next Year
- RCON $12.17
- TCRX N/A
- P/E Ratio
- RCON N/A
- TCRX N/A
- Revenue Growth
- RCON N/A
- TCRX N/A
- 52 Week Low
- RCON $1.40
- TCRX $1.02
- 52 Week High
- RCON $7.16
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- RCON 43.35
- TCRX 55.16
- Support Level
- RCON $2.15
- TCRX $1.81
- Resistance Level
- RCON $2.44
- TCRX $1.95
- Average True Range (ATR)
- RCON 0.28
- TCRX 0.11
- MACD
- RCON -0.05
- TCRX 0.01
- Stochastic Oscillator
- RCON 19.37
- TCRX 68.57
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.